Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults
NCT03393468 is a phase 1 interventional trial sponsored by National Institute of Allergy and Infectious Diseases (NIAID). As of 21 Nov 2026, it is completed. It studies Dapivirine gel in HIV Infections. The registry lists an enrollment of 16 participants at 1 site in 1 country. The registry lists a start date of 10 May 2018 and a primary completion date of 3 Dec 2018.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03393468 |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 16 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | HIV Infections |
| Drugs | Dapivirine gel |
| Start | 10 May 2018 |
| Primary completion | 3 Dec 2018 |
| Study completion | 3 Dec 2018 |
| Last update posted | 25 Oct 2021 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Ken Ho, MD
University of Pittsburgh
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Pittsburgh Crs
Pittsburgh
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03393468
Each answer restates registry values shown on this page.
What is NCT03393468?
NCT03393468 is a phase 1 interventional trial sponsored by National Institute of Allergy and Infectious Diseases (NIAID). It studies Dapivirine gel in HIV Infections.
Who leads NCT03393468?
The registry names Ken Ho, MD (study chair, University of Pittsburgh) as the overall official.
Where does NCT03393468 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03393468 study?
The registered drug and biological interventions are Dapivirine gel.
When did NCT03393468 end?
The registry lists a primary completion date of 3 Dec 2018 and a study completion date of 3 Dec 2018. The sponsor last updated the record on 25 Oct 2021.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.